Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Cartesian Therapeutics Inc.

Company price
6.35 USD -0.01 ( 0.08%)
Last update at 2026-11-13T21:00:00Z
VOLUME
106818
Market Cap
238.71M

Momentum Score

…

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
6.16
Low
6.40
High
52 Week Price Range
5.60
Low
11.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public information on Cartesian Therapeutics Inc. (RNAC) is limited; the company describes itself as a developer of cell- and gene-based therapeutic candidates. Long-term growth drivers may include clinical development progress, regulatory approvals, platform scalability and successful commercialization, which could attract investors seeking exposure to the cell and gene therapy sector.

Material risks include early-stage clinical and regulatory uncertainty, high cash burn and financing needs, manufacturing complexity for cell therapies and intense competition in the biotech sector.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
6.36
Dividend Yield
-
Revenue TTM
1.48M
Revenue Per Share
0.06
Gross Profit TTM
-66.91M
Debt / Equity
-0.10
ROE
-7029.26%
Net Debt
-112.46M
ROCE
-49.56%
Diluted EPS TTM
-5.67

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -139.50M -77.14M -238.71M 34.77M -9.72M
Net income -130.30M -77.42M -219.71M 35.38M -25.69M
Selling general administrative 31.47M 30.13M 40.58M 23.86M 20.94M
Gross profit 2.80M 38.91M 24.45M 108.74M 85.08M
Reconciled depreciation 2.96M 1.15M 0.84M 1.29M 1.25M
Ebit -139.50M -77.14M -85.72M 14.87M -4.58M
Ebitda -136.54M -75.99M -84.88M 16.16M -3.33M
Depreciation and amortization 2.96M 1.15M 0.84M 1.29M 1.25M
Non operating income net other - - - 23.26M -2.28M
Operating income -86.70M -43.90M -86.42M 14.54M -4.60M
Other operating expenses 89.50M 82.81M 112.42M 96.24M 89.67M
Interest expense - 0.00M 2.83M 3.03M 2.84M
Tax provision -9.19M 0.29M -19.00M -0.61M 15.97M
Interest income 6.58M 7.39M - 0.98M 2.80M
Net interest income 6.58M 7.39M -2.83M -3.03M -2.84M
Income tax expense -9.19M 0.29M -19.00M -0.61M 15.97M
Total revenue 2.80M 38.91M 26.00M 110.78M 85.08M
Total operating expenses 89.50M 82.81M 112.42M 96.24M 89.67M
Cost of revenue - - 1.55M 2.04M -
Total other income expense net -52.79M -33.24M -149.46M 23.26M -2.28M
Net income from continuing ops -130.30M -77.42M -219.71M 35.38M -25.69M
Net income applicable to common shares - - - 35.38M -25.69M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 296.41M 435.02M 305.05M 165.89M 159.88M
Intangible assets 93.90M 150.60M 150.60M - -
Other current assets 3.02M 3.14M 4.97M 3.78M -
Total liab 422.65M 441.82M 745.23M 72.06M 137.36M
Total stockholder equity -126.24M -6.80M -440.18M 93.83M 22.52M
Other current liab 9.50M 19.84M 60.58M - -
Common stock 0.00M 0.00M 0.02M - -
Capital stock 0.00M 0.00M 0.02M 0.01M 0.01M
Retained earnings -822.37M -692.07M -614.65M -394.94M -430.32M
Good will 48.16M 48.16M 48.16M - -
Cash 125.14M 212.61M 76.91M 106.44M 114.06M
Total current liabilities 14.94M 22.98M 68.21M 25.08M 72.25M
Current deferred revenue - - 2.31M - -
Net debt -112.46M -198.63M -65.96M - -
Short term debt 4.15M 2.85M 2.17M - -
Short long term debt - - - 8.48M 5.96M
Short long term debt total 12.68M 13.98M 10.96M - -
Other stockholder equity 700.71M 689.89M -117.80M - -
Total current assets 129.28M 216.63M 90.73M 148.14M 144.44M
Long term investments 0.00M 2.00M 2.00M 2.00M 2.00M
Short term investments - - 0.00M 28.16M 14.00M
Net receivables 1.11M 0.87M 8.85M 6.60M 9.91M
Long term debt - - - 17.79M 19.67M
Accounts payable 1.29M 0.29M 3.15M 0.32M 0.22M
Accumulated other comprehensive income -4.58M -4.62M -4.60M - -
Non currrent assets other 99.45M 2.19M 1.38M 1.34M 1.47M
Non current assets total 167.13M 218.40M 214.32M 17.75M 15.44M
Capital lease obligations 12.68M 13.98M 10.96M 11.66M 9.65M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -8.74M 34.61M -13.80M -16.05M
Change to liabilities - - - 1.70M 1.44M
Total cashflows from investing activities -5.45M -8.74M - -15.00M -17.14M
Net borrowings - 0.00M - - -
Total cash from financing activities -8.05M 168.43M -13.14M 39.22M 52.90M
Change to operating activities - - - - -0.39M
Net income -130.30M -77.42M -219.71M 35.38M -25.69M
Change in cash -87.41M 135.99M -29.75M -7.40M -24.63M
Begin period cash flow 214.28M 78.29M 108.04M 115.44M 140.06M
End period cash flow 126.87M 214.28M 78.29M 108.04M 115.44M
Total cash from operating activities -73.94M -23.67M -51.16M -31.63M -60.38M
Issuance of capital stock 0.00M 164.44M 20.25M 38.98M 51.96M
Depreciation 2.96M 1.15M 0.84M 1.29M 1.25M
Other cashflows from investing activities - 0.35M - -13.80M -16.05M
Change to inventory - - -3.85M 0.92M 0.21M
Change to account receivables -0.24M 7.98M 0.73M 3.32M -2.69M
Sale purchase of stock - 0.00M -6.17M 0.19M 0.16M
Other cashflows from financing activities -7.75M 43.99M 34.61M -0.11M -17.14M
Change to netincome - - - -8.88M 11.07M
Capital expenditures 5.45M 9.09M 0.21M 1.20M 1.08M
Change receivables - - - 3.32M -2.69M
Cash flows other operating - - - -64.06M -45.83M
Exchange rate changes - - - - -0.00M
Cash and cash equivalents changes - - - -7.42M -24.63M
Change in working capital -8.06M -5.79M 4.97M -60.38M -48.19M
Stock based compensation 10.52M 6.58M 22.52M 11.19M 7.72M
Other non cash items 60.14M 51.52M 159.21M 2.29M 2.13M
Free cash flow -79.39M -32.77M -51.37M -32.83M -61.47M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
RNAC
Cartesian Therapeutics Inc.
-0.01
0.08%
6.35 - 25.06 161.62 31.26 107.99 1.77
NVO
Novo Nordisk A/S
0.98
2.41%
41.63 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-4.02
0.74%
538.60 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
4.28
0.45%
955.47 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
64.70
7.19%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Cartesian Therapeutics Inc.

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.

7495 New Horizon Way, Frederick, MD, United States, 21703

301 348 8698

75

Name Title Year Born
Dr. Carsten Brunn Ph.D. President, CEO & Director 1972
Mr. Blaine T. Davis Chief Financial Officer 1975
Dr. Metin Kurtoglu M.D., Ph.D. Chief Operating Officer 1979
Yi Zhang Ph.D. Senior Director of Technology NA
Dr. Chris Jewell Ph.D. Chief Scientific Officer 1982
Mr. Matthew Bartholomae J.D. General Counsel & Secretary NA
Dr. Milos Miljkovic M.D., Ph.D. Chief Medical Officer 1984
Dr. Carsten Brunn Ph.D. President, CEO & Chairman of the Board 1971
Mr. Blaine T. Davis Chief Financial Officer 1974
Dr. Emily English Ph.D. Chief Operating Officer 1980

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…